Empowering patients through pharmacovigilance, transparency, and health literacy: a narrative review.

IF 2.2 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Current Medical Research and Opinion Pub Date : 2025-07-01 Epub Date: 2025-07-28 DOI:10.1080/03007995.2025.2534468
Magdia De Jesus, Golam Rabbani, Bertha Ferrer, Annlouise R Assaf, Mehnaz Bader, Brett R South, David P Leventhal, Paula Boyles, Stephen J Watt, Aida Habtezion
{"title":"Empowering patients through pharmacovigilance, transparency, and health literacy: a narrative review.","authors":"Magdia De Jesus, Golam Rabbani, Bertha Ferrer, Annlouise R Assaf, Mehnaz Bader, Brett R South, David P Leventhal, Paula Boyles, Stephen J Watt, Aida Habtezion","doi":"10.1080/03007995.2025.2534468","DOIUrl":null,"url":null,"abstract":"<p><p>At the intersection of pharmacovigilance (PV), Participant Data Return (PDR), and health literacy lies a social contract in healthcare. This implicit agreement reflects the shared responsibilities of pharmaceutical companies, healthcare providers, and patients to protect individual rights while promoting collective well-being. PV, PDR, and health literacy form a triad that ensures patients are not only protected but actively informed and engaged in their healthcare journey, fostering transparency, trust, and empowerment. PV, as a cornerstone of drug safety, upholds this social contract by continuously monitoring, identifying, and mitigating adverse reactions through collaboration with patients and healthcare providers. By encouraging patient participation in adverse event reporting, PV systems strengthen safety surveillance and reinforce the reciprocal nature of trust and accountability in healthcare. PDR strengthens this relationship by promoting ethical transparency in clinical trials. It gives participants access to their own data, supporting informed decisions and increasing public confidence in research. Health literacy empowers individuals by helping them understand and act upon health information. By leveraging tools and strategies that simplify complex medical data, pharmaceutical companies fulfill their responsibility to equip patients with the knowledge to make informed healthcare decisions. In doing so, all three honor the social contract by fostering equitable access to information and promoting patient-centered care. This manuscript highlights how PV, PDR, and health literacy work together to uphold ethical healthcare practices. Each contributes to a system built on trust, transparency, and shared responsibility; core values that reinforce positive patient outcomes and the foundation of a fair, effective healthcare ecosystem.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1249-1259"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2534468","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

At the intersection of pharmacovigilance (PV), Participant Data Return (PDR), and health literacy lies a social contract in healthcare. This implicit agreement reflects the shared responsibilities of pharmaceutical companies, healthcare providers, and patients to protect individual rights while promoting collective well-being. PV, PDR, and health literacy form a triad that ensures patients are not only protected but actively informed and engaged in their healthcare journey, fostering transparency, trust, and empowerment. PV, as a cornerstone of drug safety, upholds this social contract by continuously monitoring, identifying, and mitigating adverse reactions through collaboration with patients and healthcare providers. By encouraging patient participation in adverse event reporting, PV systems strengthen safety surveillance and reinforce the reciprocal nature of trust and accountability in healthcare. PDR strengthens this relationship by promoting ethical transparency in clinical trials. It gives participants access to their own data, supporting informed decisions and increasing public confidence in research. Health literacy empowers individuals by helping them understand and act upon health information. By leveraging tools and strategies that simplify complex medical data, pharmaceutical companies fulfill their responsibility to equip patients with the knowledge to make informed healthcare decisions. In doing so, all three honor the social contract by fostering equitable access to information and promoting patient-centered care. This manuscript highlights how PV, PDR, and health literacy work together to uphold ethical healthcare practices. Each contributes to a system built on trust, transparency, and shared responsibility; core values that reinforce positive patient outcomes and the foundation of a fair, effective healthcare ecosystem.

通过药物警戒、透明度和卫生素养赋予患者权力:叙述性回顾。
在药物警戒(PV)、参与者数据返回(PDR)和健康素养的交叉点上存在着医疗保健中的社会契约。这一隐含协议反映了制药公司、医疗保健提供者和患者在促进集体福祉的同时保护个人权利的共同责任。PV、PDR和健康素养形成了一个三位一体,确保患者不仅受到保护,而且积极知情并参与其医疗保健旅程,促进透明度、信任和赋权。PV作为药物安全的基石,通过与患者和医疗保健提供者合作,持续监测、识别和减轻不良反应,维护了这一社会契约。通过鼓励患者参与不良事件报告,PV系统不仅加强了安全监测,而且加强了医疗保健中信任和问责制的互惠性质。PDR通过促进临床试验的伦理透明度来加强这种关系。它使参与者能够获得自己的数据,支持明智的决策并增强公众对研究的信心。卫生知识素养通过帮助个人理解卫生信息并据此采取行动,增强了个人的权能。通过利用简化复杂医疗数据的工具和策略,制药公司履行了自己的责任,为患者提供知识,帮助他们做出明智的医疗保健决策。在这样做的过程中,这三个国家都通过促进公平获取信息和促进以患者为中心的护理来履行社会契约。这份手稿强调PV、PDR和健康素养如何共同维护道德医疗实践。每一个都有助于建立一个建立在信任、透明和共同责任基础上的系统;核心价值观可以加强患者的积极结果,并为公平、有效的医疗保健生态系统奠定基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Medical Research and Opinion
Current Medical Research and Opinion 医学-医学:内科
CiteScore
4.40
自引率
4.30%
发文量
247
审稿时长
3-8 weeks
期刊介绍: Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信